Finding clarity amidst complexity

Sagacity: the quality of discernment, of finding sound judgment within complexity. We chose the name deliberately. After more than two decades bringing diagnostics to market, I’ve come to believe that modern healthcare doesn’t suffer from a shortage of innovation. It suffers from a shortage of clarity about how to connect that innovation to the patients who need it.

The gap between a great test and a found patient

I’ve spent my career on the commercial side of diagnostics: strategy, launch, adoption. From that vantage point you see something the lab bench doesn’t always show. A brilliant test is worthless until the right patient is actually identified and reached. The science is often the easy part. The hard part is the path: the route from a population of undiagnosed people to a clinician who can act.

That pathway, in rare disease especially, is long and tangled. There are more than 10,000 rare diseases, affecting roughly 1 in 10 Americans, and far too often the patient is never connected to the answer that already exists.

Clarity is a strategy, not a slogan

Shortening that pathway is the work I find worth doing. It means uniting the parts that usually operate in isolation (industry, clinicians, and the technology that can finally read a whole population at once) around a single, measurable goal: getting the right patient to the right care, sooner.

It also means rigor. Innovation and access only matter if the result is trustworthy: definitions that experts have approved, cohorts you can reproduce and defend. Clarity, here, is not a marketing word. It is a discipline, the work of making complexity legible enough that people can act on it.

A path, not a maze

Our logo renders a path of waypoints because that’s the experience we’re building toward: not a maze to get lost in, but a clear route from a question (who are the patients we haven’t reached yet?) to an answer that serves a measurable outcome.

For the patient at the end of that path, the difference between found and unfound isn’t abstract. That’s why we do this work, and why we do it with both ambition and integrity.

— Raymond Tarr, CEO & Founder, Sagacity Diagnostics

Sources

1. National Organization for Rare Disorders (NORD), Rare Disease Facts and Statistics.

This article reflects the author’s perspective and is not medical advice.